HolderBook

Sio Capital Management, LLC

Reported holdings as of Q2 2026, from 31 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1482416
Reported value
$604.3M
Positions
59
Top 10 weight
48.6%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
ANTERIS TECHNOLOGIES GLOBALAVR$54.6M5,545,9849.04%+4.76pp7q+3.0%+$1.6M
CENCORA INCCOR$49.1M173,5888.13%+3.58pp3q+72.0%+$20.6M
MAXIMUS INCMMS$38.5M715,2676.36%-0.70pp8q-7.0%-$2.9M
ALLOGENE THERAPEUTICS INCALLO$27.7M13,323,4314.59%-newNEW
GLOBUS MED INCGMED$23.8M301,8163.95%-newNEW
GSK PLCGSK$22.9M436,7003.79%+0.73pp2q+13.2%+$2.7M
TYRA BIOSCIENCES INCTYRA$22.2M695,3153.68%+0.35pp10q+14.8%+$2.9M
WAYSTAR HLDG CORPWAY$19.0M925,8343.15%-2.53pp3q-43.6%-$14.7M
SELLAS LIFE SCIENCES GROUP I PUTSLS$18.2Moptions only3.01%-newOPTIONS
IDEAYA BIOSCIENCES INCIDYA$17.9M480,3832.96%-newNEW
ORUKA THERAPEUTICS INCORKA$16.9M177,1182.79%+1.86pp3q+33.7%+$4.2M
THE CIGNA GROUPCI$15.9M57,7502.63%-newNEW
SANOFI SASNY$15.5M364,2002.57%+0.92pp5q+52.0%+$5.3M
ICON PUB LTD COICLR$15.3M88,1862.53%-2.33pp3q-71.2%-$37.9M
VIATRIS INCVTRS$15.2M954,2992.51%-newNEW
CROSS CTRY HEALTHCARE INCCCRN$14.5M1,098,3932.40%+0.92pp3qHELD
RAPPORT THERAPEUTICS INCRAPP$12.8M307,6572.12%+0.48pp4q-16.1%-$2.5M
ABBOTT LABORATORIESABT$11.7M128,6561.93%-0.82pp2q-31.0%-$5.3M
CELCUITY INCCELC$11.5M110,0221.90%-1.27pp4q-43.2%-$8.8M
ZIMMER BIOMET HOLDINGS INCZBH$11.3M131,4451.87%+1.06pp3q+109.9%+$5.9M
REGENERON PHARMACEUTICALSREGN$11.2M18,0001.86%-newNEW
BRISTOL-MYERS SQUIBB COBMY$11.1M193,5001.85%-newNEW
MEDTRONIC PLCMDT$11.1M142,5001.84%-newNEW
VIR BIOTECHNOLOGY INCVIR$11.0M1,075,2741.81%-0.11pp7q-28.2%-$4.3M
SENSEONICS HLDGS INCSENS$9.0M1,592,6921.50%+1.39pp3q+1275.6%+$8.4M
EYEPOINT INCEYPT$8.9M623,1301.47%+0.14pp2q-13.7%-$1.4M
CYBIN INCHELP$8.6M1,300,0001.42%-newNEW
ANI PHARMACEUTICALS INCANIP$8.1M97,3051.33%-1.60pp7q-63.4%-$13.9M
PROTARA THERAPEUTICS INCTARA$7.3M1,921,8721.21%-0.26pp3q-2.4%-$183.2K
RELMADA THERAPEUTICS INCRLMD$6.9M1,003,5621.15%+0.19pp2q+4.0%+$266.8K
TANGO THERAPEUTICS INCTNGX$6.5M208,5001.08%-newNEW
AQUESTIVE THERAPEUTICS INCAQST$6.2M1,486,1751.02%-0.12pp6q-22.7%-$1.8M
DIANTHUS THERAPEUTICS INCDNTH$5.8M59,2540.96%-3.50pp6q-84.0%-$30.3M
SIONNA THERAPEUTICS INCSION$5.6M127,8080.93%-0.76pp2q-56.6%-$7.3M
OCULAR THERAPEUTIX INCOCUL$5.3M539,4930.88%-0.30pp2q-44.3%-$4.2M
ZENAS BIOPHARMA INCZBIO$5.3M208,5570.88%-0.05pp2q-37.1%-$3.1M
BRIGHT MINDS BIOSCIENCES INCDRUG$5.2M73,9520.86%-0.04pp7q-14.1%-$851.6K
ONKURE THERAPEUTICS INCOKUR$4.9M1,078,9650.81%+0.17pp2qHELD
SAVARA INCSVRA$3.8M617,6750.63%+0.15pp7q+0.6%+$23.3K
PMV PHARMACEUTICALS INCPMVP$3.5M2,634,1370.58%+0.04pp9q-14.4%-$592.9K
AVEANNA HEALTHCARE HLDGS INCAVAH$3.2M369,0360.52%-newNEW
OVID THERAPEUTICS INCOVID$2.7M1,005,3340.45%+0.05pp7q-19.7%-$664.6K
IMMUNOME INCIMNM$2.6M124,1680.44%-0.08pp2q-24.8%-$867.6K
HIMS & HERS HEALTH INC CALLHIMS$2.6Moptions only0.43%-newOPTIONS
AN2 THERAPEUTICS INCANTX$2.6M529,9330.42%+0.10pp2q-19.4%-$616.0K
SERINA THERAPEUTICS INCSER$1.9M1,000,0000.32%+0.04pp2qHELD
ALIGOS THERAPEUTICS INCALGS$1.9M327,2370.31%-0.04pp6qHELD
IBIO INCIBIO$1.6M904,2680.26%+0.02pp3qHELD
XILIO THERAPEUTICS INCXLO$1.5M152,4640.24%+0.06pp2qHELD
ARTIVION INCAORT$1.1M48,4810.18%-newNEW
BRIDGEBIO ONCOLOGY THERAPEUTBBOT$995.4K130,6280.16%flat4qHELD
TELA BIO INCTELA$477.2K636,3000.08%+0.02pp7qHELD
ADAGIO MED HLDGS INCADGM$455.5K698,9890.08%-0.14pp3q-45.8%-$384.1K
NEUROONE MED TECHNOLOGIES CONMTC$251.6K82,7670.04%-newNEW
ENVERIC BIOSCIENCES INCENVB$248.4K180,0000.04%-newNEW
MODULAR MED INCMODD$117.9K26,1900.02%flat2qHELD
QT IMAGING HLDGS INCQTI$62.0K15,2360.01%-newNEW
ROCKET PHARMACEUTICALS INCRCKTW$1.5K400,0000.00%flat14qHELD
HUMACYTE INCHUMAW$47749,9980.00%flat14qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 55.9%Medical Devices 17.1%Wholesale & Distribution 8.1%Business Services 6.4%Software & IT Services 3.1%Healthcare Services 2.9%Insurance 2.6%Other sectors 1.5%Not classified 2.4%
 
SectorValueShare
Biotech & Pharma$337.6M55.9%
Medical Devices$103.4M17.1%
Wholesale & Distribution$49.1M8.1%
Business Services$38.5M6.4%
Software & IT Services$19.0M3.1%
Healthcare Services$17.3M2.9%
Insurance$15.9M2.6%
Other sectors$9.0M1.5%
Not classified$14.5M2.4%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+17.8%+14.8%+3.0%100%
Q1 2026-1.6%-4.6%+3.0%99%
Q4 2025+22.8%+2.4%+20.5%100%
Q3 2025+29.5%+7.8%+21.7%100%
Q2 2025-3.2%+10.5%-13.7%100%
Q1 2025-18.0%-4.6%-13.5%100%
Q4 2024-8.2%+2.1%-10.4%100%
Q3 2024+10.0%+5.4%+4.6%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$604.3M591710213448.6%45
Q1 2026$697.3M762324151545.1%44
Q4 2025$635.7M68278161053.7%48
Q3 2025$395.2M51156121659.5%44
Q2 2025$261.8M52103161258.8%44
Q1 2025$335.8M54141561164.3%45
Q4 2024$355.4M5122951060.0%45
Q3 2024$252.2M3993121867.9%45
Q2 2024$369.5M48141081668.6%45
Q1 2024$335.8M50214111458.9%45
Q4 2023$439.2M439971876.2%44
Q3 2023$323.1M521710121157.7%45
Q2 2023$393.2M46171251569.3%45
Q1 2023$202.3M441810101975.0%42
Q4 2022$270.4M4514551874.7%44
Q3 2022$314.7M497671969.9%45
Q2 2022$266.2M61171362154.8%46
Q1 2022$302.3M651510161959.4%46
Q4 2021$331.7M69221291452.2%45
Q3 2021$313.7M611320162550.0%46
Q2 2021$402.3M731619223243.6%47
Q1 2021$492.7M892219332238.1%44
Q4 2020$488.5M892511442536.4%47
Q3 2020$505.0M893324162136.7%47
Q2 2020$342.7M773015272236.9%45
Q1 2020$298.4M693613153449.8%45
Q4 2019$419.8M673214162550.9%45
Q3 2019$310.5M60239223143.6%45
Q2 2019$414.8M682421162445.6%45
Q1 2019$370.4M682226122138.6%45
Q4 2018$274.5M67000037.6%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.